ArticleEuropean urology open science2026
Impact of Photodynamic Diagnosis on Immune Cell Infiltration in BCG-treated Non-muscle-invasive Bladder Cancer.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Photodynamic diagnosis (PDD) is used during transurethral resection of bladder tumors (TURBT) to improve detection of non-muscle-invasive bladder cancer (NMIBC). Emerging evidence suggests that PDD may also influence immune activation. We investigated whether PDD is associated with immune-related changes in tumors and urine from patients with NMIBC receiving Bacillus Calmette-Guérin (BCG) immunotherapy. Methods: We retrospectively analyzed paired pre- and post-BCG samples from 156 patients with NMIBC with detailed clinical data. PDD exposure was determined from medical records and defined as PDD use within 100 days before BCG induction. PDD status was linked to existing multi-omics data, including urine proteomics (Olink), tumor ribonucleic acid (RNA) sequencing, and imaging mass cytometry (IMC) for spatial immune profiling. Findings and limitations: Urine proteomics showed post-BCG upregulation of immune-related proteins, including programmed death-1 and vascular endothelial growth factor receptor-2, in PDD-exposed patients. In contrast, RNA sequencing suggested increased post-BCG infiltration of multiple immune cell populations (B cells, T cells, cytotoxic cells, and mast cells) in No PDD patients but not in PDD-exposed patients. Consistently, IMC indicated increased infiltration of cluster of differentiation (CD)4⁺, CD8⁺, and natural killer cells post-BCG in No PDD exposed patients, with minimal changes in PDD-exposed patients. The exploratory design and potential confounding limit causal interpretation, and no clear association with clinical outcomes was demonstrated. Conclusions and clinical implications: This exploratory and biologically focused study suggests that while PDD appears to modulate the local urinary proteome, no clear shifts in tumor immune cell infiltration were observed. These findings do not support a consistent effect of PDD on the tumor immune microenvironment, and no association with clinical outcomes was observed. Determining whether the added benefit of PDD stems purely from enhanced diagnostics or includes a direct immunomodulatory effect warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.